1. Home
  2. VRTX vs MELI Comparison

VRTX vs MELI Comparison

Compare VRTX & MELI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VRTX
  • MELI
  • Stock Information
  • Founded
  • VRTX 1989
  • MELI 1999
  • Country
  • VRTX United States
  • MELI Uruguay
  • Employees
  • VRTX N/A
  • MELI N/A
  • Industry
  • VRTX EDP Services
  • MELI Catalog/Specialty Distribution
  • Sector
  • VRTX Technology
  • MELI Consumer Discretionary
  • Exchange
  • VRTX Nasdaq
  • MELI Nasdaq
  • Market Cap
  • VRTX 104.8B
  • MELI 100.1B
  • IPO Year
  • VRTX 1991
  • MELI 2007
  • Fundamental
  • Price
  • VRTX $484.24
  • MELI $2,260.00
  • Analyst Decision
  • VRTX Buy
  • MELI Strong Buy
  • Analyst Count
  • VRTX 25
  • MELI 14
  • Target Price
  • VRTX $505.61
  • MELI $2,337.86
  • AVG Volume (30 Days)
  • VRTX 1.5M
  • MELI 397.8K
  • Earning Date
  • VRTX 02-10-2025
  • MELI 02-20-2025
  • Dividend Yield
  • VRTX N/A
  • MELI N/A
  • EPS Growth
  • VRTX N/A
  • MELI 93.60
  • EPS
  • VRTX N/A
  • MELI 37.69
  • Revenue
  • VRTX $11,020,100,000.00
  • MELI $20,777,000,000.00
  • Revenue This Year
  • VRTX $9.62
  • MELI $45.33
  • Revenue Next Year
  • VRTX $9.25
  • MELI $22.20
  • P/E Ratio
  • VRTX N/A
  • MELI $59.96
  • Revenue Growth
  • VRTX 11.66
  • MELI 43.56
  • 52 Week Low
  • VRTX $377.85
  • MELI $1,324.99
  • 52 Week High
  • VRTX $519.88
  • MELI $2,374.54
  • Technical
  • Relative Strength Index (RSI)
  • VRTX 65.58
  • MELI 78.60
  • Support Level
  • VRTX $451.99
  • MELI $2,034.03
  • Resistance Level
  • VRTX $469.55
  • MELI $2,124.00
  • Average True Range (ATR)
  • VRTX 11.70
  • MELI 62.53
  • MACD
  • VRTX 0.97
  • MELI 18.72
  • Stochastic Oscillator
  • VRTX 83.48
  • MELI 79.04

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

About MELI MercadoLibre Inc.

MercadoLibre runs the largest e-commerce marketplace in Latin America, with more than 218 million active users and 1 million active sellers across 18 countries stitching into its commerce network or fintech solutions as of the end of 2023. The company operates a host of complementary businesses to its core online shop, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago and Mercado Credito), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.

Share on Social Networks: